7u04: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==IOMA class antibody ACS101== | ==IOMA class antibody ACS101== | ||
<StructureSection load='7u04' size='340' side='right'caption='[[7u04]]' scene=''> | <StructureSection load='7u04' size='340' side='right'caption='[[7u04]], [[Resolution|resolution]] 2.31Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7U04 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7U04 FirstGlance]. <br> | <table><tr><td colspan='2'>[[7u04]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7U04 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7U04 FirstGlance]. <br> | ||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7u04 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7u04 OCA], [https://pdbe.org/7u04 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7u04 RCSB], [https://www.ebi.ac.uk/pdbsum/7u04 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7u04 ProSAT]</span></td></tr> | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.31Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=PCA:PYROGLUTAMIC+ACID'>PCA</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7u04 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7u04 OCA], [https://pdbe.org/7u04 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7u04 RCSB], [https://www.ebi.ac.uk/pdbsum/7u04 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7u04 ProSAT]</span></td></tr> | |||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
A major goal of current HIV-1 vaccine design efforts is to induce broadly neutralizing antibodies (bNAbs). The VH1-2-derived bNAb IOMA directed to the CD4-binding site of the HIV-1 envelope glycoprotein is of interest because, unlike the better-known VH1-2-derived VRC01-class bNAbs, it does not require a rare short light chain complementarity-determining region 3 (CDRL3). Here, we describe three IOMA-class NAbs, ACS101-103, with up to 37% breadth, that share many characteristics with IOMA, including an average-length CDRL3. Cryo-electron microscopy revealed that ACS101 shares interactions with those observed with other VH1-2 and VH1-46-class bNAbs, but exhibits a unique binding mode to residues in loop D. Analysis of longitudinal sequences from the patient suggests that a transmitter/founder-virus lacking the N276 glycan might have initiated the development of these NAbs. Together these data strengthen the rationale for germline-targeting vaccination strategies to induce IOMA-class bNAbs and provide a wealth of sequence and structural information to support such strategies. | |||
Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein.,van Schooten J, Farokhi E, Schorcht A, van den Kerkhof TLGM, Gao H, van der Woude P, Burger JA, Meesters TGR, Bijl T, Ghalaiyini R, Turner HL, Dorning J, van Schaik BDC, van Kampen AHC, Labranche CC, Stanfield RL, Sok D, Montefiori DC, Burton DR, Seaman MS, Ozorowski G, Wilson IA, Sanders RW, Ward AB, van Gils MJ Nat Commun. 2022 Aug 3;13(1):4515. doi: 10.1038/s41467-022-32208-0. PMID:35922441<ref>PMID:35922441</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 7u04" style="background-color:#fffaf0;"></div> | |||
==See Also== | |||
*[[Antibody 3D structures|Antibody 3D structures]] | |||
== References == | |||
<references/> | |||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Homo sapiens]] | |||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Farokhi E]] | [[Category: Farokhi E]] | ||
[[Category: Stanfield RL]] | [[Category: Stanfield RL]] | ||
[[Category: Wilson IA]] | [[Category: Wilson IA]] | ||